Review



reference standard mouse il12 protein  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological reference standard mouse il12 protein
    Examination of the effect of mouse single chain <t>IL12</t> and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.
    Reference Standard Mouse Il12 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/reference standard mouse il12 protein/product/Sino Biological
    Average 93 stars, based on 2 article reviews
    reference standard mouse il12 protein - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma"

    Article Title: Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma

    Journal: International Journal of Nanomedicine

    doi: 10.2147/IJN.S388916

    Examination of the effect of mouse single chain IL12 and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.
    Figure Legend Snippet: Examination of the effect of mouse single chain IL12 and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.

    Techniques Used: Binding Assay, Fluorescence, Incubation, Labeling, Staining, Luciferase, Concentration Assay

    Comparative effects of ITGB1 KO and recombinant mouse IL12 (rmIL12) protein on the anti-tumor efficacy of EVs. ( A ) Tumor growth curves of mice bearing subcutaneous tumors of Hepa1-6-hGPC3 cells, which were treated with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs (5.0×10 10 p/animal). *,**** P < 0.05, 0.0001 vs ITGB1 − mscIL12 + HN3 + Deg EVs group. ( B ) Tumor size shown after treatment with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs. ( C ) Heat map of mouse plasma cytokine levels normalized to the control group at 48h post-second dosing (Day 9). ( D ) Flow cytometry analysis of mouse plasma cells for total CD45 + /CD4 + T-cells and CD8 + T-cells 48h after the second dosing (Day 9). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: Comparative effects of ITGB1 KO and recombinant mouse IL12 (rmIL12) protein on the anti-tumor efficacy of EVs. ( A ) Tumor growth curves of mice bearing subcutaneous tumors of Hepa1-6-hGPC3 cells, which were treated with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs (5.0×10 10 p/animal). *,**** P < 0.05, 0.0001 vs ITGB1 − mscIL12 + HN3 + Deg EVs group. ( B ) Tumor size shown after treatment with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs. ( C ) Heat map of mouse plasma cytokine levels normalized to the control group at 48h post-second dosing (Day 9). ( D ) Flow cytometry analysis of mouse plasma cells for total CD45 + /CD4 + T-cells and CD8 + T-cells 48h after the second dosing (Day 9). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Recombinant, Flow Cytometry



    Similar Products

    reference standard mouse il12 protein  (Sino Biological)
    93
    Sino Biological reference standard mouse il12 protein
    Examination of the effect of mouse single chain <t>IL12</t> and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.
    Reference Standard Mouse Il12 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/reference standard mouse il12 protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    reference standard mouse il12 protein - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Examination of the effect of mouse single chain IL12 and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.

    Journal: International Journal of Nanomedicine

    Article Title: Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma

    doi: 10.2147/IJN.S388916

    Figure Lengend Snippet: Examination of the effect of mouse single chain IL12 and HN3 nanobody on the cell-binding properties of EVs. ( A ) Schematic design of an exosomal nanobody (HN3) and mouse single chain IL12 (mscIL12), whose vesicular loading was driven by the transmembrane domains of PDGFRβ and ITGB1, respectively. ( B ) Dose-response curve of mscIL12 EVs in mouse splenocytes, analyzed using the “drc” package in R. ( C ) Representative fluorescence images of HepG2 cells after incubation with PKH67-labeled EVs. Nuclei were stained with DAPI. ( D ) Cellular NanoLuc activities in various cell lines after incubation with ITGB1 − mscIL12 + HN3 + EVs, or ITGB1 − mscIL12 + HN3 + EVs in the presence of hGPC3-Fc fusion protein. Luciferase activities were normalized to the chemiluminescence intensities of cells incubated with respective EVs alone. ( E ) Particle populations (normalized to the plasma concentration) of EVs with or without the GPC3-targeting module (HN3) in the tumor and major organs. ( F ) Representative images of healthy and tumor-bearing lungs. ( G ) Particle populations (normalized to the plasma concentration) of the ITGB1 − mscIL12 + HN3 + Deg EVs in the major organs of healthy (Control) or lung metastasized (pulmonary tumor) mice. ** P < 0.01; *** P < 0.001.

    Article Snippet: To estimate the loading efficiency of mscIL12 into EVs, reference standard mouse IL12 protein (mIL12, SinoBiological, China) of known quantity and EVs of known number of particles were analyzed by LC/MS, according to a process described elsewhere.

    Techniques: Binding Assay, Fluorescence, Incubation, Labeling, Staining, Luciferase, Concentration Assay

    Comparative effects of ITGB1 KO and recombinant mouse IL12 (rmIL12) protein on the anti-tumor efficacy of EVs. ( A ) Tumor growth curves of mice bearing subcutaneous tumors of Hepa1-6-hGPC3 cells, which were treated with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs (5.0×10 10 p/animal). *,**** P < 0.05, 0.0001 vs ITGB1 − mscIL12 + HN3 + Deg EVs group. ( B ) Tumor size shown after treatment with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs. ( C ) Heat map of mouse plasma cytokine levels normalized to the control group at 48h post-second dosing (Day 9). ( D ) Flow cytometry analysis of mouse plasma cells for total CD45 + /CD4 + T-cells and CD8 + T-cells 48h after the second dosing (Day 9). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: International Journal of Nanomedicine

    Article Title: Surface Engineering of HEK293 Cell-Derived Extracellular Vesicles for Improved Pharmacokinetic Profile and Targeted Delivery of IL-12 for the Treatment of Hepatocellular Carcinoma

    doi: 10.2147/IJN.S388916

    Figure Lengend Snippet: Comparative effects of ITGB1 KO and recombinant mouse IL12 (rmIL12) protein on the anti-tumor efficacy of EVs. ( A ) Tumor growth curves of mice bearing subcutaneous tumors of Hepa1-6-hGPC3 cells, which were treated with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs (5.0×10 10 p/animal). *,**** P < 0.05, 0.0001 vs ITGB1 − mscIL12 + HN3 + Deg EVs group. ( B ) Tumor size shown after treatment with intravenous doses of rmIL12 (70ng or 3μg per animal), control EVs (ITGB1 − Deg) or the ITGB1 − mscIL12 + HN3 + Deg EVs. ( C ) Heat map of mouse plasma cytokine levels normalized to the control group at 48h post-second dosing (Day 9). ( D ) Flow cytometry analysis of mouse plasma cells for total CD45 + /CD4 + T-cells and CD8 + T-cells 48h after the second dosing (Day 9). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: To estimate the loading efficiency of mscIL12 into EVs, reference standard mouse IL12 protein (mIL12, SinoBiological, China) of known quantity and EVs of known number of particles were analyzed by LC/MS, according to a process described elsewhere.

    Techniques: Recombinant, Flow Cytometry